A lower upfront price reduces the barrier to access
When paired with GLP-1-mediated insulin secretion, the glycemic destabilization typically associated with pure glucagon agonism is offset, allowing the energy-expenditure benefits to manifest without the counter-regulatory downside
Together, they create a stronger, more sustained GH pulse than Sermorelin alone without the appetite stimulation or cortisol spikes associated with other secretagogues like GHRP-6
Patients on Medicare who wanted Wegovy or Zepbound for chronic weight management typically paid full cash price, often $1,000 to $1,500 per month, putting these medications out of reach for most fixed-income beneficiaries
How is realism currently evaluated in decoy networks, and what heuristics matter most